Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC28A1 | O00337 | 1/20 | 0.43 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.43 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.43 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.43 |
| ▸ | CRBN | Q96SW2 | 2/20 | 0.41 |
| ▸ | DUT | P33316 | 4/20 | 0.40 |
| ▸ | P2RY2 | P41231 | 8/20 | 0.38 |
| ▸ | P2RY6 | Q15077 | 4/20 | 0.36 |
| ▸ | P2RY4 | P51582 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20281116 | 1.00 | SLC28A1 (0.43) | SLC28A1SLC28A2SLC29A1SLC28A3CRBN | |
| SCHEMBL13531639 | 1.00 | SLC28A1 (0.43) | SLC28A1SLC28A2SLC29A1SLC28A3CRBN | |
| SCHEMBL8038615 | 0.81 | TK1 (0.46) | — | |
| SCHEMBL12154833 | 0.81 | DUT (0.41) | SLC28A1SLC28A2SLC29A1SLC28A3CRBN | |
| SCHEMBL13939558 | 0.81 | SLC28A1 (0.43) | SLC28A1SLC28A2SLC29A1SLC28A3CRBN | |
| SCHEMBL14102265 | 0.81 | SLC28A1 (0.40) | SLC28A1SLC28A2SLC29A1SLC28A3CRBN | |
| SCHEMBL9452795 | 0.81 | SLC28A1 (0.46) | SLC28A1SLC28A2SLC29A1SLC28A3DUT | |
| SCHEMBL16855538 | 0.81 | DUT (0.41) | SLC28A1SLC28A2SLC29A1SLC28A3CRBN | |
| SCHEMBL31589522 | 0.79 | SLC28A1 (0.44) | SLC28A1SLC28A2SLC29A1SLC28A3DUT | |
| SCHEMBL30618187 | 0.79 | SLC28A1 (0.44) | SLC28A1SLC28A2SLC29A1SLC28A3DUT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230172961-A1 | THERAPEUTICS FOR COVID-19 | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2023-06-08 | — | — | US | disclosed |
| EP-0457326-A1 | Antiviral agents | SYNTEX (U.S.A.) INC. (US) | 1991-11-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230172961-A1 | THERAPEUTICS FOR COVID-19 | ACE, ACE2, PNP | SLC28A1 663/4885SLC28A2 558/4885SLC29A1 400/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.